Sitemap > Breaking Research > Metabolic & Hormonal Disorders
Displaying 101 - 150 of 3753 results
- In vivo gene transfer to pancreatic beta cells by systemic delivery of adenoviral vectors.
- High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation.
- Evaluation of a novel in vitro Caco-2 hepatocyte hybrid system for predicting in vivo oral bioavailability.
- Rational design of RAR-selective ligands revealed by RARbeta crystal stucture.
- Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin.
- M40403 prevents myocardial injury induced by acute hyperglycaemia in perfused rat heart.
- The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm.
- Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model.
- What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model.
- Synthesis of cinnamic acid derivatives and their inhibitory effects on LDL-oxidation, acyl-CoA:cholesterol acyltransferase-1 and -2 activity, and decrease of HDL-particle size.
- Discovery of potent and selective beta-homophenylalanine based dipeptidyl peptidase IV inhibitors.
- Substituted piperazines as novel dipeptidyl peptidase IV inhibitors.
- Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia.
- Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults.
- Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
- Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study.
- Diabetes, impaired fasting glucose, and development of cognitive impairment in older women.
- PREDICT modeling and in-silico screening for G-protein coupled receptors.
- Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes.
- Is decreased libido associated with the use of HMG-CoA-reductase inhibitors?
- Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study.
- Cholecystokinin-induced satiety is mediated through interdependent cooperation of CCK-A and 5-HT3 receptors.
- Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria.
- Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice.
- Syntaxin 4 transgenic mice exhibit enhanced insulin-mediated glucose uptake in skeletal muscle.
- Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity.
- Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.
- A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.
- Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report.
- Family 2 cystatins inhibit osteoclast-mediated bone resorption in calvarial bone explants.
- Fluoxetine attenuates thermal hyperalgesia through 5-HT1/2 receptors in streptozotocin-induced diabetic mice.
- Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
- The novel antiobesic HMR1426 reduces food intake without affecting energy expenditure in rats.
- N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.
- Dipeptidomimetic ketomethylene isosteres as pro-moieties for drug transport via the human intestinal di-/tripeptide transporter hPEPT1: design, synthesis, stability, and biological investigations.
- Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions.
- A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
- A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis.
- Diabetes mellitus and unstable coronary artery disease: improved clinical outcome of coronary artery stenting in an era of glycoprotein IIb/IIIa inhibitors and lipid-lowering therapy.
- A selective androgen receptor modulator for hormonal male contraception.
- A novel IKKbeta inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance.
- Reduction of brain injury by antithrombotic agent acutobin after middle cerebral artery ischemia/reperfusion in the hyperglycemic rat.
- Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
- The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus.
- Identification of biphenylcarboxylic acid derivatives as a novel class of bone resorption inhibitors.
- 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.
- Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models.
- Structure-activity relationships of piperazinebenzylamines as potent and selective agonists of the human melanocortin-4 receptor.
- Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target.
- Synthesis and evaluation of new hydrazide derivatives as neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 Next >